ID   FO1-12
AC   CVCL_GZ38
SY   Fo1-12; FO-1 #12
DR   cancercelllines; CVCL_GZ38
DR   TOKU-E; 3586
DR   Wikidata; Q54835102
RX   Patent=US6063375;
RX   PubMed=10746551;
RX   PubMed=10983636;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12177.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line).
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Transformant: NCIt; C44386; Gamma radiation.
CC   Derived from site: Metastatic; Iliac lymph node; UBERON=UBERON_0015878.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5619 ! MEL-CLS-1
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 12
//
RX   Patent=US6063375;
RA   Gattoni-Celli S., Newton D.A. III, McClay E.F.;
RT   "Semiallogeneic cell hybrids and related methods for treating cancer.";
RL   Patent number US6063375, 16-May-2000.
//
RX   PubMed=10746551; DOI=10.1097/00002371-200003000-00009;
RA   Newton D.A. III, Romano C., Gattoni-Celli S.;
RT   "Semiallogeneic cell hybrids as therapeutic vaccines for cancer.";
RL   J. Immunother. 23:246-254(2000).
//
RX   PubMed=10983636; DOI=10.1097/00002030-200007280-00005;
RA   Grene E., Newton D.A. III, Brown E.A., Berzofsky J.A., Gattoni-Celli S.,
RA   Shearer G.M.;
RT   "Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific
RT   cytotoxic T lymphocytes.";
RL   AIDS 14:1497-1506(2000).
//